Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GoPro Inc (GPRO) vs Viatris Inc (VTRS) Price & Performance

Viatris IncTrade

Price performance (Past 24H)

Key statistics

GoPro Inc vs Viatris Inc — how do they compare? GoPro Inc trades at $1.19 (market cap $243.50M), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 82.3× GoPro Inc's market cap, and Viatris Inc pays a 2.75% dividend while GoPro Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Viatris Inc for 57 Days on average.

GPROVTRS
Market Cap
$243.50M$20.03B
Volume
11,527,16014,109,977
Sector
TechnologyHealth
52-Week High
$2.35$18.27
52-Week Low
$0.58$9.74
Typical Hold Time
45 Days57 Days
Enterprise Value
$302.28M$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GoPro Inc

GoPro (GPRO) trades at $1.22, down 7.58% on the day, amid volatile trading following a recent surge driven by merger news and influencer investment. The stock shows bullish technical signals with oversold RSI conditions, but fundamentals remain weak with declining revenues and persistent net losses. Recent developments include a proposed $285 million merger with Starman Optical and significant stake acquisition by YouTube creator Markiplier, creating both opportunity and uncertainty for shareholders.

The outlook remains highly speculative with the merger offering potential upside but facing shareholder litigation over valuation concerns. Key risks include continued operational losses, competitive pressures from smartphones, and merger execution challenges. Analyst sentiment is mixed with only 21% buy ratings, reflecting skepticism about the company's standalone prospects versus merger-driven speculation.

Viatris Inc

Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.

The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GPRO
92% Buy8% Sell
Avg holding period · 45 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About GoPro Inc

GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.

Read more on GPRO →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →